Avidity Biosciences (RNA) Stock Forecast & Price Target $8.23 -0.09 (-1.08%) As of 12:14 PM Eastern Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Avidity Biosciences - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 10 Analyst RatingsSell1Hold4Buy5 Based on 10 Wall Street analysts who have issued ratings for Avidity Biosciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a sell rating, 4 have given a hold rating, 4 have given a buy rating, and 1 has given a strong buy rating for RNA. Consensus Price Target $46.33462.98% Upside According to the 10 analysts' twelve-month price targets for Avidity Biosciences, the average price target is $46.33. The highest price target for RNA is $74.00, while the lowest price target for RNA is $15.00. The average price target represents a forecasted upside of 462.98% from the current price of $8.23. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for RNA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Avidity Biosciences and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNA Analyst Ratings Over TimeTypeCurrent Forecast10/28/25 to 10/28/261 Month Ago9/28/25 to 9/28/263 Months Ago7/30/25 to 7/30/261 Year Ago10/28/24 to 10/28/25Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)Buy4 Buy rating(s)3 Buy rating(s)4 Buy rating(s)9 Buy rating(s)Hold4 Hold rating(s)11 Hold rating(s)12 Hold rating(s)10 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$46.33$63.75$67.60$68.84Forecasted Upside462.98% Upside657.13% Upside489.88% Upside-1.56% DownsideConsensus RatingModerate BuyHoldHoldHold RNA Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History RNA Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Avidity Biosciences Stock vs. The CompetitionTypeAvidity BiosciencesHealthcare CompaniesBroader MarketConsensus Rating Score 2.50 2.33 2.53Consensus RatingModerate BuyHoldModerate BuyPredicted Upside462.98% Upside107.33% Upside16.55% UpsideNews Sentiment RatingNeutral NewsSee Recent RNA NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings Most Recent from Each Brokerage All Show All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action 10/28/2024 - 10/28/2026 Report Date Report Date From Report Date To 1M3M6MYTD1Y2Y3Y5Y More filters Fewer filters Done 0 Results Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/28/2026 HC Wainwright4 of 5 starsMitchell S. Kapoor3 of 5 starsLower TargetBuy$25.00 ➝ $20.00+140.38%10/22/2026 Roth Capital3 of 5 starsBoobalan Pachaiyappan1 of 5 starsInitiated CoverageBuy$15.00+87.50%8/3/2026 Weiss Ratings3 of 5 stars UpgradeSell (E-) ➝ Sell (E)6/19/2026 Zacks ResearchSubscribe to MarketBeat All Access to unlock brokerage rankings UpgradeHold6/18/2026 Cantor FitzgeraldSubscribe to MarketBeat All Access to unlock brokerage rankingsKristen KluskaSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOverweight$25.00+100.32%5/15/2026 Leerink PartnersSubscribe to MarketBeat All Access to unlock brokerage rankingsJoseph SchwartzSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOutperform3/11/2026 Wells Fargo & CompanySubscribe to MarketBeat All Access to unlock brokerage rankingsYanan ZhuSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOverweight12/18/2025 EvercoreSubscribe to MarketBeat All Access to unlock brokerage rankingsJosh SchimmerSubscribe to MarketBeat All Access to unlock analyst rankingsSet Target$72.00-0.16%11/12/2025 TD CowenSubscribe to MarketBeat All Access to unlock brokerage rankings Reiterated RatingHold11/11/2025 Chardan CapitalSubscribe to MarketBeat All Access to unlock brokerage rankingsKeay NakaeSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingNeutral$72.00+3.09% Get the Latest News and Ratings for RNA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. 10/28/2025 Royal Bank Of CanadaSubscribe to MarketBeat All Access to unlock brokerage rankingsLuca IssiSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingOutperform ➝ Sector Perform$61.00 ➝ $72.00+2.86%10/28/2025 Loop CapitalSubscribe to MarketBeat All Access to unlock brokerage rankingsKeay NakaeSubscribe to MarketBeat All Access to unlock analyst rankingsSet Target$72.00+2.86%10/28/2025 Wolfe ResearchSubscribe to MarketBeat All Access to unlock brokerage rankings DowngradeStrong-Buy ➝ Hold10/27/2025 CitigroupSubscribe to MarketBeat All Access to unlock brokerage rankingsGeoff MeachamSubscribe to MarketBeat All Access to unlock analyst rankingsDowngradeBuy ➝ Hold10/27/2025 Needham & Company LLCSubscribe to MarketBeat All Access to unlock brokerage rankingsJoseph StringerSubscribe to MarketBeat All Access to unlock analyst rankingsDowngradeBuy ➝ Hold$65.00+32.25%10/27/2025 Raymond James FinancialSubscribe to MarketBeat All Access to unlock brokerage rankingsMartin AusterSubscribe to MarketBeat All Access to unlock analyst rankingsDowngradeStrong-Buy ➝ Market Perform10/27/2025 Sanford C. BernsteinSubscribe to MarketBeat All Access to unlock brokerage rankingsWilliam PickeringSubscribe to MarketBeat All Access to unlock analyst rankingsDowngradeOutperform ➝ Market Perform$52.00 ➝ $72.00+46.49%9/15/2025 Bank of AmericaSubscribe to MarketBeat All Access to unlock brokerage rankingsGeoff MeachamSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetBuy$56.00 ➝ $65.00+60.42%8/8/2025 BarclaysSubscribe to MarketBeat All Access to unlock brokerage rankingsGena WangSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingOverweight$59.00 ➝ $62.00+30.47%7/10/2025 The Goldman Sachs GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsCorinne JohnsonSubscribe to MarketBeat All Access to unlock analyst rankingsUpgradeBuy$55.00+81.67%6/10/2025 JPMorgan Chase & Co.Subscribe to MarketBeat All Access to unlock brokerage rankingsGena WangSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$57.00 ➝ $59.00+80.65%3/12/2025 BMO Capital MarketsSubscribe to MarketBeat All Access to unlock brokerage rankingsKostas BiliourisSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOutperform$72.00+143.41%3/7/2025 ScotiabankSubscribe to MarketBeat All Access to unlock brokerage rankingsLouise ChenSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageSector Outperform$70.00+130.64%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 12:26 PM ET. RNA Forecast - Frequently Asked Questions What is Avidity Biosciences' forecast for 2026? According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Avidity Biosciences is $46.33, with a high forecast of $74.00 and a low forecast of $15.00. Should I buy or sell Avidity Biosciences stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last year. There is currently 1 sell rating, 4 hold ratings, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RNA shares. Does Avidity Biosciences's stock price have much upside? According to analysts, Avidity Biosciences's stock has a predicted upside of 462.98% based on their 12-month stock forecasts. Has Avidity Biosciences been upgraded by Wall Street analysts recently? Over the previous 90 days, Avidity Biosciences's stock had 1 upgrade by analysts. What analysts cover Avidity Biosciences? Avidity Biosciences has been rated by research analysts at HC Wainwright, Roth Capital, and Weiss Ratings in the past 90 days. Do Wall Street analysts like Avidity Biosciences more than its competitors? Analysts like Avidity Biosciences more than other "healthcare" companies. The consensus rating for Avidity Biosciences is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how RNA compares to other companies. Stock Forecasts and Research Tools Related Companies Silence Therapeutics Stock Forecast Puma Biotechnology Stock Forecast Sagimet Biosciences Stock Forecast CytomX Therapeutics Stock Forecast Sensei Biotherapeutics Stock Forecast Entera Bio Stock Forecast Neurogene Stock Forecast Monopar Therapeutics Stock Forecast Aclaris Therapeutics Stock Forecast REGENXBIO Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Avidity Biosciences RecommendationsHC WainwrightRoth CapitalWeiss RatingsZacks ResearchCantor FitzgeraldWall Street ZenLeerink PartnersWells Fargo & CompanyEvercoreTD CowenChardan CapitalRoyal Bank Of CanadaWolfe ResearchLoop Capital MarketBeat monitors more than a dozen sources for Avidity Biosciences analyst ratings, with the most recent rating issued on 10/28/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
